Inclusion Criteria:

- Diagnosis of transitional cell carcinoma of the bladder, urethra, ureter or renal
pelvis; histologic documentation of metastatic/recurrent disease is not required;
clinical staging, but not pathological staging, is required

- Patients must have relapsed from or failed to achieve a complete or partial response
after one chemotherapy regimen, which must have included one of the following
chemotherapy agents: cisplatin, carboplatin paclitaxel, or gemcitabine

- >= 4 weeks since prior RT or chemotherapy

- Patients must have measurable disease

- CTC (ECOG) Performance Status =< 1

- No evidence of NYHA functional class III or IV heart disease

- Baseline EKG with QTc < 500 ms

- Non-pregnant and not nursing, as chemotherapy is thought to present substantial risk
to the fetus/infant; men and women of reproductive potential may not participate
unless they have agreed to use an effective contraceptive method while in this study

- Granulocytes > 1500/ml

- Platelet count > 100,000/ml

- Bilirubin =< Upper limits of normal (ULN)

- Serum Creatinine < 2.0 x ULN